Rheumatoid arthritis (RA) is an immune mediated joint based dreadful inflammatory disorder,
which is characterized by joint destruction, swelling, pain and remission; it resulted to shorten lifespan and
increased mortality rates. Current treatment approaches and their advancement have gained much attention in
the prevention of RA and improvement in the many RA patients life. Despite their significant merits, still
major drawbacks remain like requirement of high dose, disease remission and prominent side effects.
Emergences of lipid based vesicular nanocarriers, including liposomes, stealth liposomes, transfersomes,
ethosomes, and niosomes etc., are designed to deliver anti-rheumatic drug to the specific sites via enhanced
permeability and retention (EPR) and active targeting to achieve desirable therapeutic effect. Whereas it
avoids systemic and non target associated side effects. In addition to this, several US and others patents on
liposomes in RA are also included. Therefore, the present review gives an exhaustive account on recent
advancement in lipid containing vesicular nanocarrier’s drug delivery in the treatment of RA.